Investment Thesis — Cardinal Health, Inc.
The market is mispricing Cardinal Health by fixating on its historically thin margins and negative book value, overlooking the significant operational leverage and the impending short squeeze that could propel shares much higher. Investors are underestimating the company's ability to convert stable, high-volume revenue into disproportionately improved profitability through efficiency gains.
Catalysts
- Strong earnings beats driven by operational efficiency and margin expansion
- Significant short covering activity triggering a massive short squeeze
- Favorable contract renewals or new strategic partnerships improving profitability
Risk Factors
- Failure to achieve anticipated margin improvements or increased operating costs
- Major litigation or regulatory fines impacting financial performance
- Sustained high interest rates increasing debt servicing costs on a fragile balance sheet
Key Debates
Net Margin expands to 0.75% by Q2 2025 from operational leverage.
16.20% Fwd Revenue Growth sustains above 15% into FY25.
Negative P/B of -17.10 proves sustainable FCF generation by H1 2025.